SCHEMBL2238427

SCHEMBL2238427

CCOC(=O)[C@H](CSCc1ccccc1)NCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.53
ELANE P08246 1/20 0.50
PPARA Q07869 4/20 0.47
PPARG P37231 2/20 0.47
ACE P12821 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
PPID Q08752 1/20 0.44
MMP8 P22894 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235605 0.84 SMN1; SMN2 (0.45) PPARGSMN1; SMN2NPC1RAB9APPID
SCHEMBL2240346 0.83 ACE (0.57) PPARAPPARGACE
SCHEMBL11024016 0.82 METAP2 (0.57) METAP2ELANEPPARAPPARGACE
SCHEMBL11024021 0.82 METAP2 (0.57) METAP2ELANEPPARAPPARGACE
SCHEMBL11024018 0.82 METAP2 (0.57) METAP2ELANEPPARAPPARGACE
SCHEMBL1931193 0.81 MMP8 (0.56) ELANEPPARGSMN1; SMN2PPIDMMP8
SCHEMBL4560664 0.81 PDCD1 (0.55) PPARGSMN1; SMN2NPC1PPIDMMP8
SCHEMBL30354719 0.81 PDCD1 (0.55) PPARGSMN1; SMN2NPC1PPIDMMP8
SCHEMBL13915549 0.81 MMP8 (0.56) ELANEPPARGSMN1; SMN2PPIDMMP8
SCHEMBL8458621 0.81 METAP2 (0.50) METAP2ELANEPPARAPPARGACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200231532-A1 Supported Metal Catalysts JOHNSON MATTHEY PLC (GB) 2020-07-23 US claimed
US-20180099923-A1 Supported Metal Catalysts JOHNSON MATTHEY PLC (GB) 2018-04-12 US claimed
EP-2536500-B1 SUPPORTED METAL CATALYSTS JOHNSON MATTHEY PLC (GB) 2016-12-07 EP claimed
EP-2536500-A1 SUPPORTED METAL CATALYSTS Johnson Matthey PLC (GB) 2012-12-26 EP claimed
WO-2011101679-A1 SUPPORTED METAL CATALYSTS JOHNSON MATTHEY PLC (GB) 2011-08-25 WO claimed
US-20200231532-A1 Supported Metal Catalysts JOHNSON MATTHEY PLC (GB) 2020-07-23 US disclosed
US-20180099923-A1 Supported Metal Catalysts JOHNSON MATTHEY PLC (GB) 2018-04-12 US disclosed
EP-2536500-B1 SUPPORTED METAL CATALYSTS JOHNSON MATTHEY PLC (GB) 2016-12-07 EP disclosed
EP-2536500-A1 SUPPORTED METAL CATALYSTS Johnson Matthey PLC (GB) 2012-12-26 EP disclosed
WO-2011101679-A1 SUPPORTED METAL CATALYSTS JOHNSON MATTHEY PLC (GB) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231532-A1 Supported Metal Catalysts SOD1, HNMT, SOD3 METAP2 405/4885ELANE 1034/4885PPARA 3524/4885
US-20180099923-A1 Supported Metal Catalysts SOD1, HNMT, SOD3 METAP2 405/4885ELANE 1034/4885PPARA 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.